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Abstract 
Background: The efficacy of drug-eluting stents has been shown in randomized trials, but 
some controversy exists regarding which stent sirolimus-eluting or paclitaxel-eluting is more 
effective in unselected Turkish patients. Therefore, we investigated the clinical outcomes of 
patients who were treated with one type of these drug-eluting stents in the real world. 
Methods: We created a registry and prospectively analyzed  data on a consecutive series of 
all patients who presented to our institution with symptomatic coronary artery disease 
between February 2005 and March 2007 and who were treated with the sirolimus- or the 
paclitaxel-eluting stent. The follow-up period after stent implantation was approximately 24 
months. The primary end point was a major cardiac event, and the secondary end point was 
stent thrombosis. Informed consent was obtained from all subjects, and the study protocol 
was approved by the local ethical committee. 
Results: In total, 204 patients were treated with either the sirolimus-eluting stent (n = 103) 
or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated 
similarly by conventional technique. At 24-month follow-up, patients who received the pac-
litaxel-eluting stent showed significantly higher rates of non–Q-wave myocardial infarction 
(1.9% vs 5.9%; P: .002), target vessel revascularization (1.9% vs 4.9%; P: .002), coronary artery 
bypass graft surgery (1.9% vs 6.9%; P: .001), and late stent thrombosis (1.9% vs 3.9%, P: .002). 
Conclusions: Patients who received the sirolimus-eluting stent showed better clinical 
outcomes compared with those who had the paclitaxel-eluting-stent. 
Key words: coronary artery disease, drug-eluting stent, major adverse cardiac event, stent throm-
bosis. 
INTRODUCTION 
Because of their association with decreased in-
cidents of restenosis and repeat intervention, the siro-
limus-eluting stent (SES)1 and the paclitaxel-eluting 
stent (PES)2 have been shown to be superior to the 
bare-metal stent.  Along with the accumulation of 
clinical experiences, drug-eluting stents increasingly 
have been used for more complex lesions involving 
the left main coronary artery,3 in-stent restenosis,4 Int. J. Med. Sci. 2010, 7 
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chronic total occlusion,5 and acute myocardial infarc-
tion.6 Although several head-to-head analyses of the 
SES and the PES have been published in the medical 
literature, uncertainty remains regarding whether a 
true difference in clinical outcomes exists. The ran-
domized, multicenter REALITY trial7 did not demon-
strate a difference in clinical outcomes between pa-
tients who received the SES and those who received 
the PES. This finding has been supported by large 
registries.8,9 In contrast, a number of smaller rando-
mized studies have shown differences in end points, 
confirmed both angiographically and clinically, in 
favor of the SES.10-13 Furthermore, in meta-analyses of 
studies comparing the 2 stent types, authors have 
confirmed a clinical advantage for those who receive 
the SES.14–17 However, the long-term safety of 
drug-eluting stents has been questioned.17-19 Despite 
the results of meta-analyses of randomized studies 
that refute these concerns,20 the possible association of 
the stents with late stent thrombosis remains a limita-
tion of this new technology. The long-term outcomes 
of Turkish patients treated with the SES vs the PES in 
real-world practice are not well reported. Therefore, 
we report the 24-month outcomes of unselected pa-
tients in southern Turkey who had coronary artery 
disease that was treated with either the SES or the 
PES. 
METHODS 
Patient Population  
The study population consisted of 204 consecu-
tive series of all patients who had undergone coronary 
stent implantation for coronary artery disease be-
tween February 2005 and March 2007; 103 of the pa-
tients received the SES (CYPHER; Cordis Corpora-
tion, Johnson and Johnson, Miami Lakes, Florida), and 
the other 101 patients received the PES (TAXUS, Bos-
ton Scientific, Natick, Massachusetts). Patients were 
eligible for enrollment if there was symptomatic co-
ronary artery disease or positive functional testing, 
and angiographic evidence of a target lesion stenosis 
of ≥ 70% in a ≥ 2-mm vessel. Patients with a contrain-
dication to antithrombotic therapy were excluded 
from the study. The coronary angiograms were ob-
tained when there was evidence of ischemia. The fol-
low-up period was approximately 24 months. In-
formed consent was obtained from all subjects, and 
the study protocol was approved by the local ethical 
committee. 
Medications and Percutaneous Coronary Inter-
vention Procedure 
All patients were pretreated with aspirin and 
clopidogrel. A loading dose of 300 mg of clopidogrel 
was administered before the procedure for those who 
were not pretreated. During the procedure, a bolus 
dose of unfractionated heparin (100 U/kg) was in-
jected through a femoral or radial artery sheath, with 
a bolus repeated as needed to maintain an activated 
clotting time of 250 to 300 seconds. Patients received 
intracoronary nitroglycerin (0.1 to 0.2 mg) before ini-
tial and final angiograms to achieve maximal vasodi-
latation. The use of glycoprotein IIb/IIIa inhibitor 
(Tirofiban) was at the operator’s discretion. All pa-
tients maintained antiplatelet therapy after the pro-
cedure (aspirin 300 mg/d for 3 months, then 100 
mg/d infinitely; clopidogrel 75 mg/d for 6 to 12 
months). The percutaneous coronary intervention 
procedure and stent implantation were performed 
using standard methods, through a femoral or radial 
approach. The operators were free to use the stent 
approach and the stent (ie, SES or PES) that they con-
sidered better. 
Study End Points and Definitions 
The primary clinical end points were major ad-
verse cardiac events (MACE), including cardiac death, 
myocardial infarction (MI), and target vessel revas-
cularization (TVR). MI was defined as the elevation of 
creatine kinase (CK) > 2 times above the upper limit of 
normal with any associated elevation in the CK myo-
cardial band or the development of new pathologic Q 
waves in 2 contiguous electrocardiographic leads. 
TVR was defined as either percutaneous or surgical 
revascularization (CABG) of the stented epicardial 
vessel. The secondary end point was stent thrombosis 
(ST) (ie, acute, < 1 day; subacute, 1 to 30 days; late, ≥ 
30 days; and very late, ≥1 year). For the assigned 
study stent, device success was defined as ≤ 50% di-
ameter stenosis of the target lesion, and procedure 
success was defined as device success with no 
in-hospital MACE. The definitions of MI and ST used 
in this study were consistent with the newest con-
sensus of the Academic Research Consortium.21 All 
primary and secondary clinical end points were ad-
judicated by an independent clinical events commit-
tee blinded to the patient’s treatment assignment. 
Follow-up 
Clinical follow-up was performed at 1, 6, 12, and 
24 months by telephone contact or office visit. Rele-
vant data were collected and entered into a compute-
rized database by specialized personnel at the cardi-
ovascular interventional heart center. 
Statistical Analysis 
All statistical analyses were performed with 
SPSS for Windows (version 10.0, Chicago, USA). 
Continuous variables were described as mean (SD), Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
193
and categorical variables were reported as percen-
tages or proportions. Comparison of continuous va-
riables was performed with unpaired t tests (normal 
distribution) and the nonparametric Mann-Whitney 
test (skew distribution). Analysis of categorical va-
riables was made with Fisher’s exact test and χ2 test. 
We used Kaplan-Meier time-to-event estimates for the 
primary events at 24-month follow-up. With the 
Kaplan-Meier method and log-rank test, we com-
pared the difference between the SES and PES co-
horts. A P value < 0.05 was considered statistically 
significant. 
RESULTS 
Baseline clinical, angiographic, and lesion cha-
racteristics are shown in Tables 1 and 2. The baseline 
clinical or demographic characteristics indicated no 
statistically significant differences between patients 
who received the SES vs those who received the PES. 
Baseline angiographic characteristics were also simi-
lar according to the modified ACC/AHA (American 
College of Cardiology/American Heart Association) 
classification.22 Overall, most lesions were located in 
the left anterior descending artery and were types B1 
or C. The mean stent diameter was 30 (SD, 4) mm 
among those who received the SES and 31 (SD, 5) mm 
(P:.4) among those who received the PES (Table 2). 
The mean stent length was 26 (SD, 7) mm in the SES 
cohort and 28 (SD, 8) mm (P:0.3) in the PES cohort.  
In-Hospital Outcomes 
In-hospital outcomes were similar between the 2 
cohorts. In-hospital incidence of MACE was 1.9% for 
patients receiving the SES and 1.9% in patients re-
ceiving the PES (P: .8).  
Long-term Clinical Outcomes 
Complete clinical follow-up at 24 months was 
accomplished for 199 patients. The outcomes are re-
ported in Table 3. At 24 months, the incidence of 
MACE was 9.7% in the SES cohort and 17.8% in the 
PES cohort (P:.04). The incidence of coronary artery 
bypass graft procedures (1.9% vs 6.9%; P:.001), TVR 
(1.9% vs 4.9%; P: .002), and non–Q-wave MI (1.9% vs 
5.9%; P:.002) was significantly higher in the PES co-
hort. There were no major differences in the rates of 
death (1.9% vs 0.9%; P: .307), Q-wave MI (3.8% vs 
5.9%; P: .326), and non–TVR (1.9% vs 3.9%; P: .3). As 
reported in Table 4, the incidence of late ST at 24 
months was significantly higher in the PES cohort 
(1.9% vs 3.9%; P:.002). Between the SES and PES co-
horts, no major differences existed in the incidence of 
acute (0.9% vs 0.9%; P:1.1) and subacute (0.9% vs 
3.9%; P:.08) ST. 
Table 1. Age and Baseline Clinical Characteristics of Patients by Treatment Cohort 
Characteristic Sirolimusa 
(n = 103) 
Paclitaxelb 
(n = 101) 
P Valuec 
Age, mean (SD), yc 57  (10.9)  58 (10.2) .9 
History, No. (%)       
 Diabetes  mellitus  40  (39)  36 (36) .5 
 H ypertension 62  (60)  64 (63) .5 
 History of smoking 72  (70)  55 (54) .08 
 H yperlipidemia 67  (65)  69 (68) .8 
 Prior  MI  11 (11)  7 (7) .1 
 Prior  PTCA  9  (9)  6 (6) .6 
 Prior  CABG  8  (8)  3 (3) .2 
 SAP  29 (28)  34 (34) .2 
 USAP  59 (57)  47 (47) .08 
 MI  15 (15)  20 (20) .3 
Serum concentrations, mean (SD), mg/dL       
 Total  cholesterol  214.5  (63.6)  233.8 (57.4) .7 
 LDL  145.5 (52.3)  150.3 (48.4) .5 
 HDL  38.4 (6.2)  39.4 (8.3) .7 
 Triglyceride 161.1  (95.4)  158.6 (101.2) .6 
 Glucose  141.3 (67.3)  114.7 (46.4) .06 
Abbreviations: CABG, coronary artery bypass graft; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarc-
tion; SAP, stable angina pectoris; USAP, unstable angina pectoris. 
aIndicates patients who received sirolimus-eluting stents. Numbers in the column do not total 100% because some patients had more than 
one condition. 
bIndicates patients who received paclitaxel-eluting stents. Numbers in the column do not total 100% because some patients had more than 
one condition. 
cP < 0.05 defined as statistically significant. 
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Table 2. Baseline Angiographic Characteristics 
Characteristic  Sirolimusa 
(n = 103) 
Paclitaxelb 
(n = 101) 
P Valuec 
Site of Lesion Treated, No. (%)       
 LAD  74  (72)  76 (75)  .7 
 Cx  12  (12)  9 (9)  .5 
 RCA  17  (17)  16 (16)  .9 
LVEFd,e 68.3  (6.1)  67.4 (7.3)  .9 
Stent diameter, mme 30  (4)  31 (5)  .4 
Stent length, mme 26  (7)  28 (8)  .3 
Lesion length, mme 21  (6)  22 (7)  .4 
Type of lesion, No. (%)       
 A  0  (0)  2 (1.9)  .3 
 B1  46  (45)  47 (47)  .9 
 B2  15  (14)  11 (11)  .6 
 C  42  (41)  41 (41)  .8 
Abbreviations: Cx, left circumflex coronary artery; LAD, left anterior descending coronary artery; LVEF, left ventricular ejection fraction; 
RCA, right coronary artery. 
aIndicates patients who received sirolimus-eluting stents. 
bIndicates patients who received paclitaxel-eluting stents. 
cP < 0.05 defined as statistically significant. 
dReported as percentage. 
eData expressed as mean (SD). 
 
Table 3. Clinical Outcomes at 24-Month Follow-up 
Outcome Sirolimusa  
[No. (%)] 
Paclitaxelb  
[No. (%)] 
P Valuec 
MACE 10  (9.7)d  18 (17.8)  .04 
 Death  2  (1.9)  1 (0.9)  .307 
 M yocardial infarction       
  Q-wave  4  (3.8)  6 (5.9)  .326 
  Non–Q-wave  2  (1.9)  6 (5.9)  .002 
 Revascularization       
  Target vessel  2 (1.9)  5 (4.9)  .002 
  Non–target vessel  2 (1.9)  4 (3.9)  .3 
CABG surgery 2  (1.9)  7 (6.9)  .001 
Abbreviations: CABG, Coronary artery bypass graft; MACE, Major adverse cardiac event (ie, death, myocardial infarction, and target vessel 
revascularization. 
aIndicates patients who received sirolimus-eluting stents. Percentages in this column are based on a cohort of 103 patients. 
bIndicates patients who received paclitaxel-eluting stents. Percentages in this column are based on a cohort of 101 patients. 
cP < 0.05 defined as statistically significant. 
 
Table 4. Comparison of Secondary End Points by Cohort 
Type of Stent Thrombosis  Sirolimusa   
[No. (%)] 
Paclitaxelb  
[No. (%)] 
P Valuec 
Acute   1 (0.9)  1 (0.9)  1.1 
Subacute  1 (0.9)  4 (3.9)  .08 
Late   2 (1.9)  4 (3.9)   .002 
Very late  0 (0)  1 (0.9)  .09 
aIndicates patients who received sirolimus-eluting stents. Percentages in this column are based on a cohort of 103 patients. 
bIndicates patients who received paclitaxel-eluting stents. Percentages in this column are based on a cohort of 101 patients. 
cP < 0.05 defined as statistically significant.  
 Int. J. Med. Sci. 2010, 7 
 
 
http://www.medsci.org 
195
Discussion 
The major finding in the present study is that the 
SES was associated with better long-term safety and 
efficacy than the PES in unselected Turkish patients 
with coronary artery disease. However, despite our 
study and several others in which the SES and the PES 
have been compared, uncertainty still remains re-
garding whether any real difference in clinical out-
comes exists. Ong and colleagues8 recently compared 
the results of 2 registries SES-based RESEARCH (Ra-
pamycin-Eluting Stent Evaluated at Rotterdam Car-
diology Hospital) and PES-based T-SEARCH (Tax-
us-Stent Evaluated at Rotterdam Cardiology Hospit-
al) and showed similar adjusted clinical outcomes for 
patients who received the PES compared with those 
who received the SES. The authors suggested that the 
inferior trend in crude outcome observed for PES re-
cipients in other studies can be attributed to the 
higher risk profiles of these patients. Two randomized 
trials comparing the SES and the PES head to head 
have been published recently.7,10 Each trial equally 
showed better angiographic parameters for patients 
who received the SES vs those who received the PES, 
but regarding clinical outcomes and binary restenosis 
rates, they showed controversial results. In the 
REALITY trial,7 patients who had MI, ostial lesions, 
in-stent restenosis, or chronic total occlusion lesions 
were excluded, and there was no significant differ-
ence between the 2 types of stents in clinical outcomes 
and binary restenosis. However, in the SIRTAX trial,10 
all comers were enrolled and over 9 months, patients 
treated with the PES showed higher rates of MACE 
and binary restenosis rates than those treated with the 
SES. The superiority of the SES over the PES in clinical 
outcomes resulted mainly from differences in rates of 
target lesion revascularization; SES use did not de-
crease death and MI rates. Moreover, meta-analysis 
results showed that patients receiving the SES had a 
significantly lower risk of restenosis and TVR com-
pared with those receiving the PES and suggested that 
SES use may result in better outcomes in relatively 
complex lesions and high-risk patients.14 
In our study, no differences existed in baseline 
clinical and angiographic characteristics between 
those who received the SES and those who received 
the PES. The SES was associated with better clinical 
outcomes compared with the PES; rates of MACE 
were 9.7% vs 17.8% (P:.04). The superiority of the SES 
over the PES in clinical outcomes resulted mainly 
from differences in rates of late ST and target lesion 
revascularization. The incidence of late ST was sig-
nificantly higher at 24 months for PES recipients. No 
major differences existed in the incidence of acute and 
subacute ST between SES recipients and PES reci-
pients. In the PES cohort, the incidence of TVR was 
significantly higher due to ST.  Seven patients in the 
PES cohort and 4 patients in SES cohort were prema-
turely taken off klopidogrel therapy, and this change 
likely played a role in the MACE events observed in 
the PES and SES cohort. Of those continuing dual 
antiplatelet therapy, 96% were in the SES cohort, and 
93% were in the PES cohort. And the difference be-
tween PES and SES groups seems to be associated 
with much number of patients prematurely taken off 
klopidogrel in PES group. 
PES treatment still was associated with poor 
overall clinical outcomes compared with outcomes 
associated with SES treatment. Also, in the multiva-
riate analysis, after adjusting for clinical variables, we 
found that PES use was a predictor of MACE within 
24 months. Given that our patients tend to have 
high-risk profiles (eg, type C lesions, 41%; type Bı 
lesions,  45%;  mean [SD] lesion length, 21 [6] mm; 
hypertension, 62%; diabetes mellitus, 37%; hyperli-
pidemia, 67%; and acute MI, 17%), our results cor-
respond with those of previous randomized studies in 
which relatively high-risk patients showed better 
clinical outcomes after SES use.10, 14, 21 
Study Limitations 
The study has several limitations—mainly, the 
small number of patients, lack of direct randomiza-
tion, and relatively low compliance with angiographic 
follow-up. 
CONCLUSIONS 
On the basis of the clinical results of this 
24-month study, one might reasonably conclude that 
treating with a sirolimus-eluting stent is more effec-
tive than treating with a paclitaxel-eluting stent in 
Turkish patients. 
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